Influenza vaccine effectiveness: Maintained protection throughout the duration of influenza seasons 2010–2011 through 2013–2014

Vaccine

Volumn 34, Issue 33, 2016, Pages 3907-3912

  Radin, Jennifer M ^a   Hawksworth, Anthony W ^a   Myers, Christopher A ^a   Ricketts, Michelle N ^a   Hansen, Erin A ^a   Brice, Gary T ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

Age groups; Influenza; Postvaccination; Vaccine effectiveness

Indexed keywords

INFLUENZA VACCINE; VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG EFFICACY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFANT; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; NEWBORN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SEASON; CLINICAL TRIAL; IMMUNOLOGY; INFLUENZA, HUMAN; MIDDLE AGED; MULTICENTER STUDY; PRESCHOOL CHILD; RESPIRATORY TRACT DISEASES; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA VACCINES; INFLUENZA, HUMAN; LOGISTIC MODELS; MALE; MIDDLE AGED; RESPIRATORY TRACT DISEASES; VACCINE POTENCY; YOUNG ADULT;

EID: 84973582881     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.05.034     Document Type: Article

References (24)

1. [1] Centers for Disease Control and Prevention. Seasonal influenza Q&A. Available at: < http://www.cdc.gov/flu/about/qa/disease.htm> [accessed 20 July 2015].
2. [2] Centers for Disease Control and Prevention, CDC's Advisory Committee on Immunization Practices (ACIP) recommends universal annual influenza vaccination. Available at: , 2010 [accessed 25 June 2014].
3. [3] Castilla, J., Martinez-Baz, I., Martinez-Artola, V., Reina, G., Pozo, F., Garcia Cenoz, M., et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill, 18, 2013.
4. [4] Jimenez-Jorge, S., de Mateo, S., Delgado-Sanz, C., Pozo, F., Casas, I., Garcia-Cenoz, M., et al. Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011–2012 season in Spain, among population targeted for vaccination. BMC Infect Dis, 13, 2013, 441.
5. [5] Pebody, R., Andrews, N., McMenamin, J., Durnall, H., Ellis, J., Thompson, C.I., et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill, 18, 2013.
6. [6] Kissling, E., Valenciano, M., Larrauri, A., Oroszi, B., Cohen, J.M., Nunes, B., et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill, 18, 2013.
7. [7] Sullivan, S.G., Komadina, N., Grant, K., Jelley, L., Papadakis, G., Kelly, H., Influenza vaccine effectiveness during the 2012 influenza season in Victoria, Australia: influences of waning immunity and vaccine match. J Med Virol 86 (2014), 1017–1025.
8. [8] Song, J.Y., Cheong, H.J., Hwang, I.S., Choi, W.S., Jo, Y.M., Park, D.W., et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 28 (2010), 3929–3935.
9. [9] Osterholm, M.T., Kelley, N.S., Sommer, A., Belongia, E.A., Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 36–44.
10. [10] Spadea, A., Unim, B., Colamesta, V., Meneghini, A., D'Amici, A.M., Giudiceandrea, B., et al. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study. Vaccine 32 (2014), 5290–5294.
11. [11] Van Buynder, P.G., Konrad, S., Van Buynder, J.L., Brodkin, E., Krajden, M., Ramler, G., et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 31 (2013), 6122–6128.
12. [12] Matsushita, M., Takeuchi, S., Kumagai, N., Uehara, Y., Matsushita, C., Arise, K., et al. Prevaccination antibody titers can estimate the immune response to influenza vaccine in a rural community-dwelling elderly population. Vaccine 30 (2012), 1101–1107.
13. [13] McLean, H.Q., Thompson, M.G., Sundaram, M.E., Meece, J.K., McClure, D.L., Friedrich, T.C., et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis 59 (2014), 1375–1385.
14. [14] Belongia, E.A., Sundaram, M.E., McClure, D.L., Meece, J.K., Ferdinands, J., VanWormer, J.J., Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine 33 (2015), 246–251.
15. [15] European Centre for Disease Prevention and Control. Influenza vaccination. Available at: < http://www.ecdc.europa.eu/en/healthtopics/seasonal_influenza/vaccines/pages/influenza_vaccination.aspx> [accessed 25 June 2014].
16. [16] European Centre for Disease Prevention and Control. Seasonal influenza vaccination in Europe: overview of vaccination recommendations and coverage rates in the EU Member States for the 2012–13 influenza season. Available at: < http://ecdc.europa.eu/en/publications/Publications/Seasonal-influenza-vaccination-Europe-2012-13.pdf> [accessed 26 April 2016].
17. [17] Petrie, J.G., Ohmit, S.E., Johnson, E., Truscon, R., Monto, A.S., Persistence of antibodies to influenza hemagglutinin and neuraminidase following one or two years of influenza vaccination. J Infect Dis 212 (2015), 1914–1922.
18. [18] Bateman, A.C., Kieke, B.A., Irving, S.A., Meece, J.K., Shay, D.K., Belongia, E.A., Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010–2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010–2011 influenza season. J Infect Dis 207 (2013), 1262–1269.
19. [19] Cowling, B.J., Feng, S., Finelli, L., Steffens, A., Fowlkes, A., Assessment of influenza vaccine effectiveness in a sentinel surveillance network 2010–13, United States. Vaccine 34 (2016), 61–66.
20. [20] Sullivan, S.G., Tay, E.L., Kelly, H., Variable definitions of the influenza season and their impact on vaccine effectiveness estimates. Vaccine 31 (2013), 4280–4283.
21. [21] Beyer, W.E., de Bruijn, I.A., Palache, A.M., Westendorp, R.G., Osterhaus, A.D., Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med 159 (1999), 182–188.
22. [22] Centers for Disease Control and Prevention. Seasonal influenza vaccine dosage & administration. Q&A. Available at: < http://www.cdc.gov/flu/about/qa/vaxadmin.htm> [accessed 9 February 2015].
23. [23] Licensure of a high-dose inactivated influenza vaccine for persons aged > or = 65 years (fluzone high-dose) and guidance for use – United States, 2010. MMWR morb mortal wkly rep, vol. 59; 2010, p. 485–6.
24. [24] Faix, D.J., Hawksworth, A.W., Myers, C.A., Hansen, C.J., Ortiguerra, R.G., Halpin, R., et al. Decreased serologic response in vaccinated military recruits during 2011 correspond to genetic drift in concurrent circulating pandemic A/H1N1 viruses. PLoS ONE, 7, 2012, e34581.